Fiche publication
Date publication
mars 2025
Journal
British journal of pharmacology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr GARRIDO Carmen
,
Dr BELLAYE Pierre-Simon
,
Pr BONNIAUD Philippe
Tous les auteurs :
Boutanquoi PM, Pommerolle L, Dondaine L, Tanguy J, Bellaye PS, Biziorek L, Gautier-Isola M, Mari B, Masnikov D, Rocchi P, Finetti P, Korczak P, Vialet B, Barthelemy P, Garrido C, Bonniaud P, Burgy O, Goirand F
Lien Pubmed
Résumé
Idiopathic pulmonary fibrosis (IPF) is a fatal disease characterized by fibroblast activation and abnormal accumulation of extracellular matrix in the lungs. We previously demonstrated the importance of the heat shock protein αB-crystallin (HSPB5) in TGF-β1 profibrotic signalling, which suggests that HSPB5 could be a new therapeutic target for the treatment of IPF. The purpose of this study was thus to develop antisense oligonucleotides targeting HSPB5 and to study their effects on the development of experimental pulmonary fibrosis.
Mots clés
HSPB5, TGF‐β1, antisense oligonucleotides, heat shock protein, pulmonary fibrosis
Référence
Br J Pharmacol. 2025 03 4;:
